A Single Dose Study of Debio 1450 in Healthy Subjects

NCT02162199 | Completed Phase 1

• 2 other identifiers: Debio 1450-102217596
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

The sponsor is trying to develop a medicine for infections that are not cured by regular antibiotics. They have an experimental drug called Debio 1450 that may work. They need about 48 healthy adults to volunteer for this study. This study looks at what the body does to the drug. It measures how the amount of drug in blood and urine changes over time. From the screening visit through the follow-up visit may be up to 40 days. Volunteers go to the clinic in Baltimore for a screening visit. The study doctor chooses qualified volunteers to participate or serve as alternates. Alternates might not actually complete the study procedures. The study doctor divides participants into groups of eight. Six receive Debio 1450 and 2 receive Placebo. The drug each participant receives is decided by chance - like flipping a coin. Eligible volunteers check into the clinic for testing and those chosen to participate remain for a 5-day/ 4-night stay. The clinic serves standard meals, except when fasting is required. Participants must stay at the clinic for the length of the study. This study is a "dose escalation" study. That means that if no safety concerns come up a new group starts. Each new group of eight participants receives more capsules. The study product is contained in capsules. Each capsule contains either placebo or 40 mg Debio 1450. After fasting overnight, the first two participants in the group receive their capsules. One gets Debio 1450 and one gets Placebo. If these participants tolerate side effects for 24 hours, the remaining six participants receive their assigned capsules. The plan is to increase the dose for the next group. The study doctor reviews the measurements collected from each group after three days. He may decide to repeat, increase, or lower the dose or even stop the study. The most any participant receives is 800 mg in 20 capsules.

Conditions

Bacterial Infections

Keywords

Antibiotic; Antibiotic Resistant Bacterial Infection

Outcome Measures

Primary Outcomes (3)

• Number of participants with at least one treatment emergent adverse event (TEAE)

  within 10 days post-dose

• Maximum observed plasma concentration (Cmax) of Debio 1450

  within 60 hours post-dose

• Time of maximum observed plasma concentration (tmax) of Debio 1450

  within 60 hours post-dose

Secondary Outcomes (13)

• Area under the plasma concentration-time curve (AUC) of Debio 1450

  pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

• Percentage of AUC0-∞ that is due to extrapolation beyond the last quantifiable concentration measurement (%AUCex) of Debio 1450

  pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

• Elimination half-life (t½) of Debio 1450

  pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

• Terminal elimination rate constant (λz) of Debio 1450

  pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

• Mean residence time (MRT) of Debio 1450

  pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

Study Arms (2)

Debio 1450

EXPERIMENTAL

Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions

Drug: Debio 1450

Placebo

PLACEBO COMPARATOR

Placebo 0 mg, matching capsules, orally, once in the morning under fasted conditions

Drug: Placebo

Interventions

Debio 1450 DRUG

Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.

Debio 1450

Placebo DRUG

Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.

Placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Is a healthy adult
• Has met protocol-specified criteria for qualification and use of contraception
• Is willing and able to remain confined in the study unit for the entire duration of the treatment period and comply with restrictions related to food, drink and medications
• Has voluntarily consented to participate and provided written informed consent prior to any protocol-specific procedures

You may not qualify if:

• Has screening laboratory values outside protocol-specified limits
• Has history of a clinically significant allergic drug reaction
• Has donated a volume of plasma or whole blood within a time frame not allowed per protocol
• Has historical or current use not allowed per protocol of:
• over-the-counter medications
• certain foods; dietary, mineral or herbal supplements
• licit or illicit drugs (including experimental drugs, caffeine, nicotine and alcohol)
• Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
• the safety or well-being of the participant or study staff
• the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
• the analysis of results

Sponsors & Collaborators

• Debiopharm International SA: lead

Study Sites (1)

Early Phase Clinical Unit

Baltimore, Maryland, 21225, United States

Location

MeSH Terms

Conditions

Bacterial Infections

Interventions

afabicin

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections

Study Officials

• Azra Hussaini, MD

  Early Phase Clinical Unit - Baltimore, USA

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 10, 2014
• First Posted: June 12, 2014
• Study Start: June 1, 2014
• Primary Completion: October 1, 2014
• Study Completion: October 1, 2014
• Last Updated: October 23, 2014

Record last verified: 2014-10

Locations

US (1)